Seres Therapeutics Inc(MCRB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.28 | Insider Own | 23.57% | Shs Outstand | 9.8M | Perf Week | -15.31% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | -40.71% | Insider Trans | -0.04% | Shs Float | 7.6M | Perf Month | -39.59% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -1 | Inst Own | 11.4% | Short Float | 4.11% | Perf Quarter | -64.81% |
| Income | -0.02B | P/S | 9.36 | EPS this Y | -649.09% | Inst Trans | -0.84% | Short Ratio | 4.6 | Perf Half Y | -76.74% |
| Sales | 0.00B | P/B | 0.5 | EPS next 5Y | - | ROA | -18.31% | Short Interest | 0.31M | Perf YTD | -88.1% |
| Book/sh | 3.51 | P/C | 1.13 | EPS past 3/5Y | - | ROE | -66.57% | 52W High | -94.1% ($29.98) | Perf Year | -88.78% |
| Cash/sh | 1.57 | P/FCF | - | Sales past 3/5Y | -51.99% -52.67% | ROIC | -28.31% | 52W Low | 5.67% ($1.67) | Perf 3Y | -93.9% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 71.26% | Gross Margin | -83.17% | Volatility(W/M) | 12.77% 9.98% | Perf 5Y | -98.54% |
| Dividend TTM | - | EV/Sales | 31.2 | Sales Y/Y TTM | 448.44% | Oper. Margin | -4095.43% | ATR (14) | 0.24 | Perf 10Y | -99.21% |
| Dividend Ex-Date | - | Quick Ratio | 2.11 | EPS Q/Q | 120.7% | Profit Margin | -1192.94% | RSI (14) | 20.88 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.11 | Sales Q/Q | - | SMA20 | -24.63% ($2.35) | Beta | 0.37 | Target Price | $17 |
| Payout | - | Debt/Eq | 1.64 | Earnings | 2026/8/5 | SMA50 | -51.06% ($3.62) | Rel Volume | 1.77 | Prev Close | $1.95 |
| Employees | 66 | LT Debt/Eq | 1.3 | EPS/Sales Surpr. | 121.51% 311.17% | SMA200 | -75.09% ($7.11) | Avg Volume(3M) | 0.07M | Price | $1.77 |
| IPO | 2015/6/26 | Option/Short | Yes/Yes | Trades | 387 | Volume | 120,114 | Change | -9.23% |
🧪 A pioneer in the microbiome therapeutics field, this innovative biotech company treats infectious and metabolic diseases by restoring the gut microbial ecosystem. It developed VOWST, the world's first oral microbiome drug, and is now focused on commercializing next-generation therapies to prevent infections in patients with blood cancers.
Over the past 1 year, on the lower side
94% below its 1-year high.
Traded more than usual. That is 177% of its average volume.
MCRB has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -649.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $936. Peers typically go for $1,089. It is about in line with its own 1-year average.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.5%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #467 of 595 in the industry
Based on market cap of $18M.
KYNB#466 Kyntra Bio Inc $19M PER 0.1 MCRB#467 Seres Therapeutics Inc $18M PER - 
CNTX#468 Context Therapeutics Inc $17M PER - 
JSPR#469 Jasper Therapeutics Inc $17M PER - 
RADX#470 Radiopharm Theranostics Ltd ADR $17M PER - 
FAQ
What kind of company is MCRB?
MCRB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MCRB?
The market cap of MCRB is approximately $18M, ranking 5,246 within its sector.
What is the 52-week high and low for MCRB?
MCRB has recorded a 52-week high of $29.98 and a low of $1.67.
